Could a cream help control Early-Stage skin lymphoma?
NCT ID NCT06698822
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a cream containing tofacitinib, a drug that calms the immune system, for people with early-stage cutaneous T-cell lymphoma (CTCL). The study will include 20 adults with stage IA, IB, or IIA disease. Researchers want to see if the cream is safe and can help control the skin lymphoma without needing stronger treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tofacitinib 2% cream
What this could lead to
If it works, this could offer a new topical treatment option for early-stage cutaneous T-cell lymphoma, potentially controlling the disease with fewer side effects than systemic therapies.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The cream may not be effective or could cause skin irritation or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact